Clinical trial
SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma
NCT06422936 is registered in ClinicalTrials.gov with Highlight Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma
- Lead sponsor
- Highlight Therapeutics
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- May 27, 2024
- Completion date
- June 30, 2028
- Enrollment
- 50 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.